What Nine Years Of MDR Experience Is Changing About PMCF Planning, And Where AI fits In

By Kevin Thornton, Director of Marketing

Nearly a decade after the European Union Medical Device Regulation (EU MDR) came into effect, compliance strategies are undergoing a necessary recalibration. While early industry efforts focused on universally establishing extensive clinical data pipelines, regulatory frameworks are increasingly separating administrative compliance from true patient safety value. Crucially, while Post-Market Surveillance (PMS) remains a universal obligation across all device classes, active Post-Market Clinical Follow-up (PMCF) is only required when genuine residual clinical risks remain. For well-established legacy technologies with decades of safe performance, auditing existing commitments can eliminate redundant administrative overhead without compromising regulatory standing.

Simultaneously, the deployment of artificial intelligence (AI) and automated extraction from electronic health records is reshaping the economics of real-world evidence generation. Re-evaluate your compliance roadmap by exploring expert perspectives on navigating regulatory shifts, distinguishing core surveillance obligations, and building a defensible, value-driven clinical data strategy.